Genmab announces patent settlement agreement for ofatumumab
GSK enters patent settlement with Genentech regarding ofatumumab
28-Mar-2012
- Denmark
The case was initiated by GSK in October 2009 and has been pending before the United States District Court for the Central District of California. The settlement means that the pending court case will now be concluded. The two patents are due to expire in December 2018.
The settlement is not expected to affect Genmab's financial guidance for 2012.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.